New results from telisotuzumab adizutecan (Temab-A) and ABBV-706 demonstrate continued progress in AbbVie's antibody-drug conjugate (ADC) portfolio targeting difficult-to-treat cancers
mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma
Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant
The presentation will provide qualitative insights into its safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in patients with solid tumors
The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
Lilly's Omvoh is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis
The trial is the largest to date evaluating Leqvio and the first to focus on patient-centered outcomes
Alembic Pharmaceuticals successfully completes USFDA inspection for API-III facility
This strategic move aims to address the increasing global demand for biologics, enhancing ProBioGen's ability to support partners from cell line development t
Shelter Pharma Limited secured an order from Berlin International Medical Co D3Cure 50 ml x 30000 pcs
Subscribe To Our Newsletter & Stay Updated
